We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares

Delisted

RVLP was delisted on the 20th of October, 2023.

0 hedge funds and large institutions have $0 invested in RVL Pharmaceuticals plc Ordinary Shares in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 30 (-3)

100% less capital invested

Capital invested by funds: $613 → $0 (-$613)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
Holders Change
-3
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
3
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
XT
1
XTX Topco
Cayman Islands
-$542 -180,566 Closed
RJA
2
Raymond James & Associates
Florida
-$71 -23,696 Closed

RVLP Hedge Fund Activity: Q1 2024 in Review

0 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q1 2024, worth a combined $0 — down 100% from $613 a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of RVLP and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was XTX Topco, exiting entirely with an estimated $542 sold.

  • 0 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q1 2024, down from 3 in Q4 2023.
  • Funds reported $0 of RVL Pharmaceuticals plc Ordinary Shares stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q1 2024 and 3 closed out, a net change of -3 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q1 2024 was XTX Topco, an estimated $542 sold.

Based on aggregated 13F filings for Q1 2024.